Skip NavigationSkip to Content

Human Cripto-1 and Cripto-3 Protein Expression in Normal and Malignant Settings That Conflicts with Established Conventions

  1. Author:
    Cuttitta,Frank
    García-Sanmartín, Josune [ORCID]
    Feng,Yang
    Sunday, Mary Elizabeth
    Kim, Young S
    Martínez, Alfredo [ORCID]
  2. Author Address

    Tumor Angiogenesis Unit, Mouse Cancer and Genetics Program, National Cancer Institute/Frederick Facility, Frederick, MD 21701, USA., Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain. Duke University Medical Center, Durham, NC 27710, USA., Cancer Prevention Science Branch, Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20850, USA.,
    1. Year: 2024
    2. Date: Oct 23
    3. Epub Date: 2024 10 23
  1. Journal: Cancers
    1. 16
    2. 21
  2. Type of Article: Article
  1. Abstract:

    Background/Objectives: Cripto-1 (CR1) is a plurifunctional embryonic protein required for implantation and re-expressed in the adult during wound repair, inflammation, and tumorigenesis. CR1 and its predicted CR1 pseudogene product Cripto-3/CR3 are highly homologous proteins, and given this physical attribute, commercially available antibodies cannot discriminate between CR1 and CR3. Methods: A series of mouse monoclonal antibodies [MoAbs] were developed with a high-affinity binding that can differentiate human CR1/CR3 proteins and showed no measurable cross-reactivity. Results: Using these reagents, we confirm that CR3 is a bona fide translated protein found in human tumor tissue, cancer cell lysates, and in normal/cancer patient donor sera. We also reveal that CR1 and CR3 compete for binding to signal transduction protein Nodal, glucose-regulated protein 78Da (GRP78), and activin receptor-like kinase 4 (Alk4). Our discriminatory MoAbs provide new reagents to help clarify current CR1/CR3 protein expression vagaries in the Cripto field of study, challenging established CR1 conventions. In addition, our data validate CR3 involvement in human carcinogenesis and cell signaling pathways, with potential clinical relevance in determining cancer patient prognosis and disease severity.

    See More

External Sources

  1. DOI: 10.3390/cancers16213577
  2. PMID: 39518018
  3. PMCID: PMC11545644
  4. PII : cancers16213577

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel